Client Care






COVID-19 : How to use the test

June 5, 2020


Products Range

New product:

Ag Respi-Strip

BL-RED Range

Resist Range









Immunochromatographic Range

Pathogens detection

40/41 Adenovirus


Clostridium difficile

Cryptosporidium & Giardia

Rotavirus & 40/41 Adenovirus


Helicobacter pylori

Influenza A & B viruses


Respiratory Adenovirus

Rotavirus & Adenovirus


Respiratory Syncytial Virus (RSV)

Streptococcus (group A)

Trypanosoma brucei gambiense (HAT)

Quatro-VeT (Veterinary)

Molecular Range

Pseudomonas aeruginosa

Scientific partners



PARADIS (Biowin)

AquaVir (FP7)

Nareb (FP7)

Euroleish (H2020-MSCA-ITN)

ebolaMoDRAD (IMI-2)


Products  >  Molecular-Field  >  Pseudomonas aeruginosa  >  Science

Pseudomonas aeruginosa - Science


• Pre-Real-Time PCR steps standardization for appropriate interpretation of mexA and mexX gene expression by mex Q-Test in P. aeruginosa.

L. Avrain, D. Hocquetb, T. Laurent, T. Leclipteux, P. Mertens

20th ECCMID, 10-13 April 2010

Pre-Real-Time PCR


• Influence of antibiotic treatments on gene expression of RND efflux pumps in successive isolates of Pseudomonas aeruginosa collected from patients with nosocomial pneumonia hospitalized in Intensive Care Units from Belgian Teaching Hospihospitalized Hospitals.

M. Riou, L. Avrain, F. El Garch, Y. Glupczynski, J.P. Pirnay, D. De Vos, P.M. Tulkens, F. Van Bambeke

20th ECCMID, 10-13 April 2010

Influence of antibiotic treatments


• Assessment of Antibiotic Resistance of Clinical Isolates of Pseudomonas aeruginosa (PA) Collected from Intensive Care Units (ICU) Patients with Nosocomial Pneumonia in 5 Belgian Hospitals during the 2004 - 2008 Period using EUCAST and CLSI breakpoints.

M. Riou, S. Carbonnelle, L. Avrain, J.P. Pirnay, D. De Vos, A. Simon, D. Piérard, F. Jacobs, A. Dediste,F. Van Bambeke, P.M. Tulkens

26th ICC, 19 June 2009

Influence of antibiotic treatments in Belgian Hospitals-PA


• Impact du traitement antibiotique sur le niveau de résistance des souches de Pseudomonas aeruginosa (P.a.) collectées par paires chez des patients souffrant d'une pneumonie nosocomiale dans cinq hôpitaux belges.

M. Riou, Y. Glupczynski, S. Carbonnelle, L. Avrain, J.P. Pirnay, D. De Vos, A. Simon, D. Pierard, F. Jacobs, A. Dediste, F. Van Bambeke, P.M. Tulkens

29th RICAI, 3-4 December 2009

Impact du traitement antibiotique-P.a.



• In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy
Int. J. Antimicrob. Agents 2010 36: 513–522

Riou M, Carbonnelle S , Avrain L, Mesarosa N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens P, Van Bambeke F, Glupczynski Y


Pseudomonas aeruginosa causes severe nosocomial pneumonia in Intensive Care Unit (ICU) patients, with an increased prevalence of multiresistant strains. We examined the impact of the use of antipseudomonal antibiotic(s) on the susceptibility of P. aeruginosa isolated from ICU patients with clinically suspected hospital-acquired pneumonia collected in five teaching hospitals (110 non-duplicate initial isolates; 62 clonal pairs of initial and last isolates during treatment). Minimum inhibitory concentrations (MICs) were determined for amikacin, ciprofloxacin, meropenem, piperacillin/tazobactam (TZP), cefepime and ceftazidime (used in therapy) as well as five reporter antibiotics (aztreonam, colistin, gentamicin, piperacillin and ticarcillin) using Clinical and Laboratory Standards Institute (CLSI) methodology. Susceptibility was assessed according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI breakpoints. Resistance rates prior to treatment exceeded 25% for cefepime, ceftazidime, piperacillin, ticarcillin and aztreonam (EUCAST and CLSI) and for gentamicin, TZP and colistin (EUCAST only). The highest rates of cross-resistance were noted for ceftazidime and cefepime and the lowest rate for amikacin. Mean MIC values were systematically higher in isolates from patients previously exposed (1 month) to the corresponding antibiotic. For clonal pairs, a systematic increase in MIC between initial and last isolates (significant for amikacin, cefepime, meropenem and TZP) was noted. There was a significant correlation between the use of antibiotics (adjusted for respective proportional use of each drug) and loss of susceptibility at the population level when using EUCAST breakpoints. The high level of resistance of P. aeruginosa in ICU patients with nosocomial pneumonia as well as its further increase during treatment severely narrows the already limited therapeutic options. Further observational studies and the development of early diagnosis for resistant isolates are warranted.


More information :



Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                 

Web traffic Optimisation

Design, Programming & hosting
Impact communication